4//SEC Filing
DE CLARA MAXIMILIAN 4
Accession 0001236031-09-000018
CIK 0000725363other
Filed
Sep 24, 8:00 PM ET
Accepted
Sep 25, 4:28 PM ET
Size
6.4 KB
Accession
0001236031-09-000018
Insider Transaction Report
Form 4
CEL SCI CORPcvm
DE CLARA MAXIMILIAN
DirectorPresident
Transactions
- Award
Options
2009-07-06+500,000→ 3,326,249 totalExercise: $0.38Exp: 2019-07-06→ Common Stock (500,000 underlying)
Footnotes (2)
- [F1]Exercisable date to be determined based on the following: one third of the options can be exercised when the first 400 patients are enrolled in CEL-SCI's Phase III head and neck cancer clinical trial. One third of the options can be exercised when all of the patients have been enrolled in the Phase III clinical trial. One third of the options can be exercised when the Phase III trial is completed.
- [F2]The Board of Directors has identified the successful Phase III clinical trial for Multikine to be the most important corporate event to create shareholder value. These stock options were given to key employees on July 6, 2009 as performance based options related to the progress of CEL-SCI's Phase III Multikine cancer trial. The option award was not valid until after the shareholders had approved the plans pursuant to which these options were issued. Approval for the issuance of these options was received from the shareholders on September 14, 2009.
Documents
Issuer
CEL SCI CORP
CIK 0000725363
Entity typeother
Related Parties
1- filerCIK 0001236031
Filing Metadata
- Form type
- 4
- Filed
- Sep 24, 8:00 PM ET
- Accepted
- Sep 25, 4:28 PM ET
- Size
- 6.4 KB